A review of the effects of tibolone on the skeleton

被引:3
作者
Devogelaer, JP [1 ]
机构
[1] Univ Catholique Louvain, St Luc Univ Hosp, Rheumatol Unit, B-1200 Brussels, Belgium
关键词
bone mineral density; dual energy X-ray absorptiometry (DXA); fractures; postmenopausal osteoporosis; quantitative computed tomography; tibolone;
D O I
10.1517/eoph.5.4.941.30166
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a frequent condition, which can lead to significant morbidity and even to increased mortality, owing to its complications (i.e., the fractures). Several therapies, mostly antiresorbing agents such as oestrogens, anti-oestrogens (chiefly raloxifene), calcitonin and bisphosphonates, are recognised for the treatment of the condition. More recently, parathyroid hormone has been added to the armamentarium of therapeutic agents. However, except for oestrogens, no other therapy alleviates climacteric symptoms. There is, therefore, some room for a therapeutic agent dealing with both osteoporosis and menopausal symptoms. Tibolone might be such an agent. However, so far, no fracture data are available; all existing studies have shown a positive action of tibolone on bone mineral density. No study has been tailored to study the antifracture efficacy. The Long Term Intervention on Fractures with Tibolone (LIFT) study has been started with the aim at filling the gap between bone mineral density maintenance and bone fracture prevention. At the same time, this study should help to understand the similarities and differences between tibolone and oestrogens as far as long-term bone action and safety are concerned, and should particularly help to clarify a possible link between tibolone use and breast cancer.
引用
收藏
页码:941 / 949
页数:9
相关论文
共 54 条
  • [1] Tibolone: a review
    Albertazzi, P
    Di Micco, R
    Zanardi, E
    [J]. MATURITAS, 1998, 30 (03) : 295 - 305
  • [2] ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
  • [3] Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial
    Beardsworth, SA
    Kearney, CE
    Purdie, DW
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (07): : 678 - 683
  • [4] Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
  • [5] Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study
    Berning, B
    Kuijk, CV
    Kuiper, JW
    Bennink, HJTC
    Kicovic, PM
    Fauser, BCJM
    [J]. BONE, 1996, 19 (04) : 395 - 399
  • [6] Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone
    Berning, B
    von Kuijk, C
    Kuiper, JW
    Bennink, HJTC
    Fauser, BCJM
    [J]. MATURITAS, 1999, 31 (02) : 151 - 159
  • [7] Tibolone: Prevention of bone loss in late postmenopausal women
    Bjarnason, NH
    Bjarnason, K
    Haarbo, J
    Rosenquist, C
    Christiansen, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (07) : 2419 - 2422
  • [8] The response in spinal bone mass to Tibolone treatment is related to bone turnover in elderly women
    Bjarnason, NH
    Bjarnason, K
    Hassager, C
    Christiansen, C
    [J]. BONE, 1997, 20 (02) : 151 - 155
  • [9] The influence of physical activity on the response of bone mineral density to 5 years tibolone
    Brooke-Wavell, K
    Prelevic, GM
    Bartram, C
    Ginsburg, J
    [J]. MATURITAS, 2000, 35 (03) : 229 - 235
  • [10] Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
    Castelo-Branco, C
    Vicente, JJ
    Figueras, F
    Sanjuan, A
    de Osaba, MJM
    Casals, E
    Pons, F
    Balasch, J
    Vanrell, JA
    [J]. MATURITAS, 2000, 34 (02) : 161 - 168